Form 4: Dare Bioscience Director William H. Rastetter Acquires 40,000 Stock Options

Director William H. Rastetter acquired 40,000 stock options in Dare Bioscience, Inc. on June 5, 2024.

Summary

• On June 5, 2024, William H. Rastetter, a director of Dare Bioscience, Inc., acquired 40,000 stock options.
• The options have an exercise price of $0.43.
• The options vest on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to continued service as a director.
• The options will become exercisable in full upon a change in control of the issuer.
• The expiration date for the options is June 5, 2034.
• Following the transaction, Rastetter beneficially owns 40,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction (stock option grant) for a director, indicating alignment with company goals but not necessarily a strong positive or negative signal.

Positives

• The acquisition of stock options by a director signals confidence in the company's future prospects.

Industry Context

This is a standard transaction for directors of publicly traded companies. Stock options are often used as part of compensation packages to align the interests of directors with those of shareholders.

Comparison to Industry Standards

• Director compensation packages often include stock options to incentivize performance and align interests with shareholders.
• The vesting schedule and change in control provisions are typical for stock option grants.

Stakeholder Impact

• The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates